Drug-induced lupus: An update

Autoimmunity Reviews

Volumn 10, Issue 1, 2010, Pages 46-50

  Katz, Uriel ^a,b   Zandman Goddard, Gisele ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti TNF; Autoimmunity; Biologics; Drug induced lupus; SLE

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTICONVULSIVE AGENT; ANTINUCLEAR ANTIBODY; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOBAZAM; CLOZAPINE; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; FLUOROURACIL; HISTONE ANTIBODY; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERLEUKIN 2; ISONIAZID; LISINOPRIL; METHYLDOPA; MINOCYCLINE; PENICILLIN G; PROCAINAMIDE; QUINIDINE; SALAZOSULFAPYRIDINE; TERBINAFINE; TOCAINIDE; UNINDEXED DRUG; ZAFIRLUKAST;

ARTHRALGIA; CLINICAL FEATURE; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPOCOMPLEMENTEMIA; LUPUS LIKE SYNDROME; MYALGIA; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-ARRHYTHMIA AGENTS; HUMANS; HYDRALAZINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCAINAMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78149360234     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.07.005     Document Type: Review

References (27)

1. Sarzi-Puttini P., Atzeni F., Capsoni F., Lubrano E., Doria A. Drug-induced lupus erythematosus. Autoimmunity 2005, 38:507-518.
2. Rubin R.L. Drug-induced lupus. Dubois' Systemic Lupus Erythematosus 2007, 870-900. Lippincott, Williams & Wilkins, Philadelphia, PA. D.J. Wallace, B.H. Hahn (Eds.).
3. Marzano A.V., Vezzoli P., Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009, 18:935-940.
4. Gomez-Puerta J.A., Burlingame R.W., Cervera R. Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev 2008, 7:606-611.
5. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
6. Zarrabi M.H., Zucker S., Miller F., Derman R.M., Romano G.S., Hartnett J.A., Varma A.O. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 1979, 91:194-199.
7. Papagoras C., Voulgari P.V., Drosos A.A. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010, 9:574-582.
8. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009, 84:979-984.
9. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
10. Ramos-Casals M., Brito-Zeron P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
11. Ramos-Casals M., Roberto Perez A., Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
12. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
13. Gonnet-Gracia C., Barnetche T., Richez C., Blanco P., Dehais J., Schaeverbeke T. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008, 26:401-407.
14. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., Boucquillard E., Siame J.L., Mariette X. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545-R551.
15. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
16. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005, 52:2192-2201.
17. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den Bossche N., Van den Bosch F., Veys E.M., De Keyser F. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
18. Benucci M., Saviola G., Baiardi P., Cammelli E., Manfredi M. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. Clin Rheumatol 2008, 27:91-95.
19. Eriksson C., Engstrand S., Sundqvist K.G., Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005, 64:403-407.
20. Haraoui B., Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006, 18:96-100.
21. Bleumink G.S., ter Borg E.J., Ramselaar C.G., Ch Stricker B.H. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001, 40:1317-1319.
22. Williams E.L., Gadola S., Edwards C.J. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009, 48:716-720.
23. Fernandez D., Perl A. Metabolic control of T cell activation and death in SLE. Autoimmun Rev 2009, 8:184-189.
24. Gorelik G., Richardson B. Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun Rev 2009, 8:196-198.
25. Zhou Y., Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 2008, 7:376-383.
26. Das J., Arora P., Gracias D., Praveen A., Raj B.P., Martin E., Pal R. Endogenous humoral autoreactive immune responses to apoptotic cells: effects on phagocytic uptake, chemotactic migration and antigenic spread. Eur J Immunol 2008, 38:3561-3574.
27. Kocharla L., Mongey A.B. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?. Lupus 2009, 18:169-171.